CompletedNCT00107926
Licarbazepine added to lithium or valproate for mania
About this title
Read the official source — NCT00107926Medication studyAges 18–70Multiple countriesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- La Palma and 43 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 343
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Austria, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00107926
- Official title
Show the full official title
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
La Palma, United States · Kansas City, United States · Shreveport, United States
43 more locations
- Somerville, United States
- Farmington Hills, United States
- Staten Island, United States
- Madison, United States
- Bellaire, United States
- Dallas, United States
- Bellevue, United States
- Kirkland, United States
- West Allis, United States
- Vienna, Austria
- Greater Sudbury, Canada
- Kelowna, Canada
- London, Canada
- Montreal, Canada
- Vancouver, Canada
- Verdun, Canada
- Bogotá, Colombia
- Medellín, Colombia
- Pareira, Colombia
- Brno, Czechia
- Hradec Králové, Czechia
- Prague, Czechia
- Berlin, Germany
- Bochum, Germany
- Dresden, Germany
- Ingolstadt, Germany
- Mannheim, Germany
- Würzburg, Germany
- Guatemala City, Guatemala
- Lima, Peru
- Moscow, Russia
- Yaroslavl, Russia
- Bojnice, Slovakia
- Michalovce, Slovakia
- Durban, South Africa
- Dnipro, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Caracas, Venezuela
- Czechia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Licarbazepine and Placebo.
Who was this study for?
Listed age limits: 18 years to 70 years.
